Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Adalimumab/Infliximab

Various toxicities

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Boivineau G, et al. Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID. Journal of Crohn's and Colitis 16: 1816-1824, No. 12, Dec 2022. Available from: URL: 10.1093/ecco-jcc/jjac089 Boivineau G, et al. Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID. Journal of Crohn's and Colitis 16: 1816-1824, No. 12, Dec 2022. Available from: URL: 10.1093/ecco-jcc/jjac089
Metadaten
Titel
Adalimumab/Infliximab
Various toxicities
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57915-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Apixaban

Case report

Tozinameran

Case report

Lithium

Case report

Multiple drugs

Case report

Multiple drugs